Effect of Ataluren on dystrophin mutations
Open Access
- 28 April 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (12), 6680-6689
- https://doi.org/10.1111/jcmm.15319
Abstract
Duchenne muscular dystrophy is a severe muscle wasting disease caused by mutations in the dystrophin gene (dmd). Ataluren has been approved by the European Medicines Agency for treatment of Duchenne muscular dystrophy. Ataluren has been reported to promote ribosomal read‐through of premature stop codons, leading to restoration of full‐length dystrophin protein. However, the mechanism of Ataluren action has not been fully described. To evaluate the efficacy of Ataluren on all three premature stop codons featuring different termination strengths (UAA > UAG > UGA), novel dystrophin‐deficient zebrafish were generated. Pathological assessment of the muscle by birefringence quantification, a tool to directly measure muscle integrity, did not reveal a significant effect of Ataluren on any of the analysed dystrophin‐deficient mutants at 3 days after fertilization. Functional analysis of the musculature at 6 days after fertilization by direct measurement of the generated force revealed a significant improvement by Ataluren only for the UAA‐carrying mutant dmdta222a. Interestingly however, all other analysed dystrophin‐deficient mutants were not affected by Ataluren, including the dmdpc3 and dmdpc2 mutants that harbour weaker premature stop codons UAG and UGA, respectively. These in vivo results contradict reported in vitro data on Ataluren efficacy, suggesting that Ataluren might not promote read‐through of premature stop codons. In addition, Ataluren had no effect on dystrophin transcript levels, but mild adverse effects on wild‐type larvae were identified. Further assessment of N‐terminally truncated dystrophin opened the possibility of Ataluren promoting alternative translation codons within dystrophin, thereby potentially shifting the patient cohort applicable for Ataluren.Keywords
Funding Information
- National Health and Medical Research Council of Australia (APP1144159, APP1136567)
This publication has 41 references indexed in Scilit:
- Suppression of premature termination codons as a therapeutic approachCritical Reviews in Biochemistry and Molecular Biology, 2012
- Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathyBrain, 2012
- Mechanisms of Aminoglycoside Ototoxicity and Targets of Hair Cell ProtectionInternational Journal of Otolaryngology, 2011
- Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMDMolecular Therapy, 2011
- Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124Proceedings of the National Academy of Sciences of the United States of America, 2010
- The zebrafish dystrophic mutantsoftymaintains muscle fibre viability despite basement membrane rupture and muscle detachmentDevelopment, 2009
- DMDexon 1 truncating point mutations: Amelioration of phenotype by alternative translation initiation in exon 6Human Mutation, 2009
- Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppressionProceedings of the National Academy of Sciences of the United States of America, 2009
- Structure and Function of Skeletal Muscle in Zebrafish Early LarvaeThe Journal of general physiology, 2008
- Stages of embryonic development of the zebrafishDevelopmental Dynamics, 1995